Psychedelic News2022-06-10T08:33:44+00:00

Industry News

News and Press Releases

  • PSYENCE GROUP ANNOUNCES DTC ELIGIBILITY APPROVAL IN THE U.S.

Psyence Group Announces DTC Eligibility Approval in the U.S

February 9, 2022|

TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).

  • PSYENCE_UPDATE_FEATURE

Psyence looks to expand capital market opportunities in the UK and Europe

January 21, 2022|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.

News and Press Releases

  • PSYENCE GROUP ANNOUNCES DTC ELIGIBILITY APPROVAL IN THE U.S.

Psyence Group Announces DTC Eligibility Approval in the U.S

February 9, 2022|

TORONTO, 09 February 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States (“US”).

  • PSYENCE_UPDATE_FEATURE

Psyence looks to expand capital market opportunities in the UK and Europe

January 21, 2022|

TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.

Psyence In The News

Psyence wins ISO certification from British Standards Institute for psilocybin production facility

Psyence Group Inc’s Yasin Khan tells Proactive the life science biotechnology company’s psilocybin production facility has officially received International Organization for Standardization (ISO) 22000:2018 certification through the British Standards Institute (BSI).

ISO 22000 is a globally accepted international standard that specifies the requirements for food safety management systems. Psyence’s facility, which is federally licensed to cultivate and export Psilocybin mushrooms for the legal medical and research markets, is based in Southern Africa and has been operational since January 2021.

Read More

Psyence Group’s functional mushroom brand to be sold in South Africa’s largest coffee retail chain

Psyence Group Inc, CEO Neil Maresky caught up with Proactive and shares his thoughts about Psyence’s joint venture functional mushroom brand Goodmind and its partnership with one of Africa’s largest coffee retail chains vida e caffè.
The Goodmind product is available in sachet format and as a functional mushroom cappuccino.
Read More

Psyence Group begins trading on the OTCQB platform in New York to satisfy investor demand

Psyence Group Inc CFO Warwick Corden-Lloyd joined Proactive New York to discuss the group’s plan to increase exposure to US investors by beginning to trade on the OTCQB Venture Market platform. In addition, the Toronto-based firm said it has applied for Depository Trust Company (DTC) eligibility to simplify the trading process in the US. Corden-Lloyd says Psyence will have a presence at two upcoming conferences to discuss its recent advancements: the “The End in Mind – Psychedelic Medicines & Ending Well” and “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms.

Read More

Psyence Group launches its functional mushroom products under the GOODMIND banner in South Africa

Psyence Group Inc (CSE:PSYG)’s Tony Budden caught up with Proactive New York to discuss the the international biotechnology company with operations in South Africa’s launch of its range of functional mushroom products under the GOODMIND banner.

Read More

In this interview with Proactive Investors, Dr. Neil Maresky talks about his appointment as CEO of Psyence Group.

He shares insights about his career, including spending more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky, a South African trained doctor, tells Proactive about his motivation to join Psyence, stating that it is because of its ability to potentially impact mental health including depression, anxiety, PTSD, and end-of-life care.

Take a listen here.

Read More

Psyence Group ‘delighted’ to reach psilocybin product development agreement with Jamaican government

Interested in Psyence’s collaboration with the Jamaican government’s Scientific Research Council (SRC)? Take a listen to the Proactive Investors interview with Psyence CEO Jody Aufrichtig and learn more about the agreement which will consist of three key initiatives: developing psilocybin-based nutraceuticals; identifying and collecting Jamaica’s psychedelic and psychoactive mushrooms, and sorting protocols to optimize spawn production of rare psychedelic mushroom species.

Read More

Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027

14 April 2021

We are honoured to be referenced in an article about the growing psychedelics sector, with the market for psychedelic drugs expected to reach $6.9 billion by 2027.

Read More

Psychedelic Finance chats to Psyence CEO Jody Aufrichtig

19 January 2021

Find out why our CEO believes in psychedelics, what Psyence stands for and how the lessons Jody learnt in the cannabis industry are helping him navigate the psychedelics opportunity in this in depth Q&A with Psychedelic Finance.

Read More

Psyence looking to be a major player in psychedelics using their federally licensed facilities

11 February 2021

Interested in learning more about Psyence? Take a listen to our CEO Jody Aufrichtig’s conversation with Steve Darling from Proactive.

Read More

Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller

19 February 2021

Psyence joined the CSE’s Barrington Miller to tell our story and share what we believe sets Psyence apart from other companies in this space: we are licensed, operational and global. Want to know more?

Take a look at this video:

Go to Top